Hormonal
Tirzepatide (5-15 mg once weekly) significantly reduces HbA1c (by 1.5-2.5%) and body weight (by 15-25%) in patients with type 2 diabetes and obesity, outperforming standard therapies like semaglutide and insulin.
Tirzepatide is a once-weekly injection approved for T2DM and obesity. It works by mimicking hormones that regulate blood sugar and appetite. Clinical trials show it lowers HbA1c by up to 2.5% and causes significant weight loss (15-25%). It is more effective than semaglutide and insulin for these metrics. Common side effects are gastrointestinal (nausea, diarrhea) but often improve over time. Weight regain is common if the drug is stopped, suggesting long-term use may be necessary for sustained results.
Across studies, tirzepatide reduced glycated hemoglobin (HbA1c) by up to 2.5% and body weight by more than 20%. ... SURPASS-2 directly compared tirzepatide with semaglutide 1 mg and found tirzepatide to be superior, with reductions of 2.46% versus 1.86%, respectively.
Why this rating
Based on multiple large-scale Phase 3 RCTs (SURPASS, SURMOUNT programs) with thousands of participants.
Source
A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
Mrudula Thiriveedi et al. · Annals of Medicine and Surgery · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →